Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Home Depot Inc (HD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Home Depot Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Home Depot Inc trades at $343.81 (market cap $342.31B). The key difference: Home Depot Inc is far larger — about 8.6× Alnylam Pharmaceuticals, Inc.'s market cap, and Home Depot Inc pays a 2.71% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | HD | |
|---|---|---|
Market Cap | $39.89B | $342.31B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $423.42 |
52-Week Low | $278.09 | $297.51 |
Enterprise Value | $38.15B | $403.87B |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Home Depot (HD) trades at $343.30, up 1.35% on the day, with mixed technical signals showing a bearish overall trend but bullish moving averages. The company reported $159.51B in revenue for 2025 with a net income margin of 8.41%, though earnings per share missed expectations in Q3 2025 but beat in subsequent quarters. Recent news highlights institutional trading activity and concerns over weak big-ticket demand and rising mortgage rates impacting home improvement stocks.
The outlook remains cautious with a consensus price target of $370.59 suggesting upside potential, but risks include margin pressure from investments and housing market sensitivity. Long-term growth relies on professional customer demand and housing tailwinds, though near-term volatility may persist due to economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →
